Fernanda das Neves Carneiro Haum

Dr. Fernanda das Neves Carneiro Haum


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DGDaniel da Motta Girardi
Daniel da Motta Girardi
LSLara P. Sousa
Lara P. Sousa
TMThiago A. Miranda
Thiago A. Miranda
FHFernanda das Neves Carneiro Haum
Fernanda das Neves Carneiro Haum
GPGabriel Clemente de Brito Pereira
Gabriel Clemente de Brito Pereira
Allan PereiraAllan Pereira
Allan Pereira
Hepatocellular carcinoma often develops in the context of chronic liver disease. It is the sixth most frequently diagnosed cancer and the third most common cause of cancer-related mortality worldwide. Although the mainstay of therapy is surgical resection, most patients are not eligible because of liver dysfunction or tumor extent. Sorafenib was the first tyrosine kinase inhibitor that improved the overall survival of patients who failed to respond to local therapies or had advanced disease, and for many years, it was the only treatment approved for the first-line setting. However, in recent years, trials have demonstrated an improvement in survival with treatments based on immunotherapy and new targeting agents, thereby extending the treatment options. A phase III trial showed that a combination of immunotherapy and targeted therapy, including atezolizumab plus bevacizumab, improved survival in the first-line setting, and is now considered the new standard of care. Other agents and combinations are being tested, including the combination of nivolumab plus ipilimumab and tremelimumab plus durvalumab, and they reportedly have clinical benefits. The aim of this manuscript is to review the latest approved therapeutic options in first- and second-line settings for advanced HCC and discuss future perspectives.